Listed below are the Topics in Antiviral Medicine Editorial Board members and their financial relationships with ineligible companies within the past 24 months from the date of disclosure. Members of the TAM Editorial Board are compensated for their work on the journal.
The ACCME defines ineligible companies as “those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.”
Editor in Chief
Douglas D. Richman, MD
Professor of Pathology and Medicine
University of California San Diego
San Diego, California
Dr Richman has been a consultant to Antiva Biosciences, Gilead Sciences, Inc, and Merck and Co, Inc. (Updated April 20, 2022)
Members
Constance A. Benson, MD
Professor of Medicine
University of California San Diego
San Diego, California
Dr Benson has served on advisory and data safety monitoring boards for GlaxoSmithKline/ViiV Healthcare, received research grants awarded to her institution from Gilead Sciences, Inc., and serves as a consultant to NDA Partners, LLC. Her spouse has served as a consultant to CytoDyn, AbbVie and Sempra Energy; owns stock options in Antiva Biosciences and CytoDyn; has served on the board for Gilead Sciences, Inc., with payment remitted to his institution; and has served on data and safety monitoring boards for Gilead Sciences, Inc., and VIR. (Updated April 20, 2022)
Martin S. Hirsch, MD
Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Dr Hirsch has no relevant financial affiliations to disclose. (Updated April 20, 2022)